Sopharma Trading AD closed 2022 reporting 13% growth in revenue on individual level. It reached 1 085 440 ths. BGN compared to 956 778 ths. BGN as per the 2021 audited report. The revenue only in December increased by 26% to 103 065 ths. BGN vs. 81 830 ths. BGN in the same month of the previous year.
The profit before taxes for 2022 on individual level reached 34 615 ths. BGN and represents 38% growth compared to the company’s financial result before the impairment loss in 2021 of 25 115 ths. BGN. The profit before taxes in the last month of 2022 increased to 5 178 ths. BGN.
Two events have a significant impact on the financial result of Sopharma Trading AD for 2022. In December the subsidiary “Sopharmacy 63” distributed dividend at the amount of 3 917 ths. BGN to the company. As of 31.12.2022 Sopharma Trading АD also carried out an impairment test of its investments in the Serbian subsidiary Sopharma Trading d.o.o according to IAS 36 “Impairment of Assets” which resulted in impairment loss of 14 228 ths. BGN. Thus, the profit before taxes for 2022 on individual level prior to the impact of the impairment loss and the income from dividend amounted to 20 387 ths. BGN.
The asset impairment test also resulted in impairment loss that will impact the consolidated statements of the Sopharma Trading Group: 13 328 ths. BGN in impairment of goodwill in Serbia and 8 245 ths. BGN in impairment of Property, Plant and Equipment in Serbia.
